Omalizumab Dose‐Related Efficacy in a Cohort of Children With Severe Food Allergy: OSAFA Observational Study
Allergy · 2026-04 · 81 (4) · 1239-1246
DOI: 10.1111/all.70228 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Allergy, online erschienen am 19.01.2026. Verfasst von Stefania Arasi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Allergy Division, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy. Hauptthemen laut MEDLINE: Omalizumab, Food Hypersensitivity, Anti-Allergic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: Allegria ONLUS, Milano, Italy.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
We recently published on the clinical efficacy of a 1‐year‐long evaluation of 65 asthmatics with severe IgE‐mediated food allergy (FA) under Omalizumab: Omalizumab is safe and able to increase reactivity threshold, allows safe food introduction, and improves quality of life (OSAFA‐study, ClinicalTrials.gov , NCT06316414). Herein, we assess Omalizumab dose–related efficacy during the first year Omalizumab treatment in achieving food desensitization in patients with severe FA.
Methods
Children (6–18 years) with severe asthma and severe allergy to ≥ 1 food allergen were screened. Oral food challenges (OFCs), skin prick test (SPT), complete blood count, chemistry, total and specific IgE were measured at baseline and at 12 months of Omalizumab.
Results
Seventy‐six patients (previously published cohort plus 11 newly‐enrolled patients) were included (OSAFA [Omalizumab in Severe Asthmatics with Food Allergy] study). 69.7% were male; mean age (SD) 12.2 [4.19] years. 77.6% were allergic to 2+ foods. Total IgE median was 644 kU/L. After adjusting for confounders, such as age, sex, and co‐existing allergies, a significant association was observed between the achievement of desensitization and the dosage (mg/month) of Omalizumab (OR: 1.151, 95% CI: 1.066–1.258), while no significant effect was observed for total IgE levels at the baseline (OR: 0.999, 95% CI: 0.998–1.001).
Conclusions
The findings of this study indicate that the efficacy of Omalizumab is independent, all else being equal, from total IgE levels, suggesting that body weight is the most appropriate parameter for calculating its dosage in the treatment of patients with severe FA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Allergy Division, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
- Department of Paediatrics, San Carlo Hospital, Potenza, Italy.
- Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
- Department of Political Science, University of Teramo, Teramo, Italy.
ORCID-Profile: Stefania Arasi, Carol Bitetti, Lucia Lo Scalzo, Alessandra Spagnoli, Elena Fabrizi, Alessandro Fiocchi, Arianna Cafarotti
Förderung
- Allegria ONLUS, Milano, Italy
Zitieren
APA
Arasi, S., Bitetti, C., Lo Scalzo, L., Spagnoli, A., Fabrizi, E., Fiocchi, A., & Cafarotti, A. (2026). Omalizumab Dose‐Related Efficacy in a Cohort of Children With Severe Food Allergy: OSAFA Observational Study. Allergy, 81(4), 1239-1246. https://doi.org/10.1111/all.70228
Vancouver
Arasi S, Bitetti C, Lo Scalzo L, Spagnoli A, Fabrizi E, Fiocchi A, et al. Omalizumab Dose‐Related Efficacy in a Cohort of Children With Severe Food Allergy: OSAFA Observational Study. Allergy. 2026;81(4):1239-1246. doi:10.1111/all.70228
BibTeX
@article{Arasi2026,
author = {Arasi, Stefania and Bitetti, Carol and Lo Scalzo, Lucia and Spagnoli, Alessandra and Fabrizi, Elena and Fiocchi, Alessandro and Cafarotti, Arianna},
title = {Omalizumab Dose‐Related Efficacy in a Cohort of Children With Severe Food Allergy: OSAFA Observational Study},
journal = {Allergy},
year = {2026},
volume = {81},
number = {4},
pages = {1239--1246},
doi = {10.1111/all.70228}
}
EUVIMED